Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy
Open Access
- 22 February 2016
- journal article
- letter
- Published by Springer Nature in Nature Biotechnology
- Vol. 34 (4) , 430-434
Abstract
Adoptive immunotherapy with genetically engineered T cells has the potential to treat cancer and other diseases. The introduction of Strep-tag II sequences into specific sites in synthetic chimeric antigen receptors or natural T-cell receptors of diverse specificities provides engineered T cells with a marker for identification and rapid purification, a method for tailoring spacer length of chimeric receptors for optimal function, and a functional element for selective antibody-coated, microbead-driven, large-scale expansion. These receptor designs facilitate cGMP manufacturing of pure populations of engineered T cells for adoptive T-cell therapies and enable in vivo tracking and retrieval of transferred cells for downstream research applications.Keywords
This publication has 22 references indexed in Scilit:
- The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive forIn VivoAntitumor ActivityCancer Immunology Research, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Lowest numbers of primary CD8+ T cells can reconstitute protective immunity upon adoptive immunotherapyBlood, 2014
- Ultra-sensitive detection of rare T cell clonesJournal of Immunological Methods, 2012
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cellsBlood, 2011
- Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassetteJournal of Molecular Medicine, 2008
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Design of HIV Vectors for Efficient Gene Delivery into Human Hematopoietic CellsMolecular Therapy, 2002
- Antiviral Effect and Ex Vivo CD4 + T Cell Proliferation in HIV-Positive Patients as a Result of CD28 CostimulationScience, 1996
- The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cellsJournal of Immunological Methods, 1990